First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik A…
Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik A…
Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreem…
Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreeme…
The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Na…
Eckert & Ziegler BEBIG has received CE approval for the world's first applicators manufactured by 3D printing and design…
Eckert & Ziegler AG (ISIN DE0005659700), a global radioisotope specialist headquartered in Berlin, Germany, has formed a…
Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related appli…
Die Berliner Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), ein Spezialist für isotopentechnische…
Eckert & Ziegler Radiopharma GmbH has received approval from the Federal Institute for Drugs and Medical Devices (BfArM)…
Eckert & Ziegler Radiopharma GmbH has received a recommendation from the European Medicines Agency for approval of its p…